Navigation Links
Programs for development of health in poor countries not effective

Millennium Development Goals Memorandum signed between 189 countries from Developed and developing countries five years ago for providing better health conditions to people in poor countries have not attained any effective in providing health relief to these people had been reported in the Journal British Medical Journal//.

If these countries are to make meaningful progress on the strategy aims - the Millennium Development Goals - most will have to raise funds or be forced to reallocate monies from other programs, argue the authors, all experts from the World Health Organization.

The Millennium Development Goals were agreed between 189 of the world's major western nations and much of the developing world. Those specifically on health were designed to take action on five key fronts: reducing mother and infant deaths, tackling child poverty, preventing the spread of HIV/AIDS, and controlling malaria and tuberculosis.

Current approaches must change if the goals are to be achieved more quickly. In curbing the spread of HIV/AIDS, treatment with first-line antiretrovirals has now become at least as cost effective as some of the well known preventive interventions, such as voluntary counselling and testing, says the authors. Educating sex workers, mass media messages, and treating people for other sexually transmitted infections, should also be the focus of new campaigns.

Mothers and newborns must have both basic and emergency medical services as a priority, and all children should get measles immunization and micronutrients as a matter of course, say the authors.

The fight against malaria demands a much larger injection of resources than currently available, and substantial investment is also needed to meet targets on reducing tuberculosis, they argue.

The papers, which examine the cost-effectiveness of health policies in Africa and South-East Asia, preview a two-day Paris summit next week (14-15 November 2005) t
'"/>




Page: 1 2

Related medicine news :

1. Disease Management Programs – Effective for Heart Patient
2. Cardiac – Rehabilitation Programs Beneficial for Heart Patient
3. NRIs Called Upon To Participate In AIDS Awareness Programs
4. Rich People Benefit From Cancer Programs
5. Germany Donates $870,00 For HIV Prevention Programs In Myanmar
6. Singapore To Offer More Patients Access To Chronic Disease Management Programs
7. Worksite Wellness Programs Plays a Vital Role in Improving the Health of the Staff
8. Stroke Rehab Programs Should Be Generalized
9. Students Light Up Despite School Anti-Smoking Programs
10. Canada Witness Delay in Flu Vaccination Programs
11. HIV Prevention through Abstinence-only Programs
Post Your Comments:
Breaking Medicine Technology:Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Exploring standards to advance microbial genomics 9201 1Exploring standards to advance microbial genomics 9201 2Exploring standards to advance microbial genomics 9201 3Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 1Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 2Cochlear Americas Announces FDA Clearance of the Cochlear 28TM 29 Baha 28R 29 BP100 Sound Processor the Industrys First Programmable Bone Conduction 51324 3Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 1Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 2Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 51322 3
Other Medicine Technology:Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 2Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 3Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 4Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 5Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 6Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 7Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid,Arthritis 8Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 2Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 3Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 4Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 5Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 6Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 7Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B,Showed Significant Reductions in Disease Activity in Patients with,Active Systemic Lupus Erythematosus 8